亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

无容量 医学 化疗 内科学 肿瘤科 临床终点 肺癌 危险系数 随机对照试验 癌症 置信区间 免疫疗法
作者
Hossein Borghaei,Kenneth J. O’Byrne,Luis Paz‐Ares,T. Ciuleanu,Xinmin Yu,Adam Płużański,Adnan Nagrial,Libor Havel,Rubén Dario Kowalyszyn,C. Audigier Valette,Julie R. Brahmer,Martin Reck,S. Ramalingam,Li Zhang,Ives Ntambwe,Sridhar K. Rabindran,Faith E. Nathan,David Balli,Yi‐Long Wu
出处
期刊:ESMO open [Elsevier BV]
卷期号:8 (6): 102065-102065 被引量:2
标识
DOI:10.1016/j.esmoop.2023.102065
摘要

•Primary endpoint of OS with nivolumab plus chemotherapy versus chemotherapy in nonsquamous metastatic NSCLC was not met.•Descriptive analyses showed improved OS with nivolumab plus chemotherapy in all-randomized and squamous NSCLC populations.•PFS and DOR favored nivolumab plus chemotherapy versus chemotherapy in all-randomized and squamous NSCLC populations.•No firm associations were found between select somatic mutations, TMB, or LIPI score and OS with nivolumab plus chemotherapy.•Safety was consistent with previous reports, and no new safety signals were identified. BackgroundIn CheckMate 227 Part 1, first-line nivolumab plus ipilimumab prolonged overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC) and tumor programmed death-ligand 1 (PD-L1) expression ≥1% versus chemotherapy. We report results from CheckMate 227 Part 2, which evaluated nivolumab plus chemotherapy versus chemotherapy in patients with metastatic NSCLC regardless of tumor PD-L1 expression.Patients and methodsSeven hundred and fifty-five patients with systemic therapy-naive, stage IV/recurrent NSCLC without EGFR mutations or ALK alterations were randomized 1 : 1 to nivolumab 360 mg every 3 weeks plus chemotherapy or chemotherapy. Primary endpoint was OS with nivolumab plus chemotherapy versus chemotherapy in patients with nonsquamous NSCLC. OS in all randomized patients was a hierarchically tested secondary endpoint.ResultsAt 19.5 months’ minimum follow-up, no significant improvement in OS was seen with nivolumab plus chemotherapy versus chemotherapy in patients with nonsquamous NSCLC [median OS 18.8 versus 15.6 months, hazard ratio (HR) 0.86, 95.62% confidence interval (CI) 0.69-1.08, P = 0.1859]. Descriptive analyses showed OS improvement with nivolumab plus chemotherapy versus chemotherapy in all randomized patients (median OS 18.3 versus 14.7 months, HR 0.81, 95.62% CI 0.67-0.97) and in an exploratory analysis in squamous NSCLC (median OS 18.3 versus 12.0 months, HR 0.69, 95% CI 0.50-0.97). A trend toward improved OS was seen with nivolumab plus chemotherapy versus chemotherapy, regardless of the tumor mutation status of STK11 or TP53, regardless of tumor mutational burden, and in patients with intermediate/poor Lung Immune Prognostic Index scores. Safety with nivolumab plus chemotherapy was consistent with previous reports of first-line settings.ConclusionsCheckMate 227 Part 2 did not meet the primary endpoint of OS with nivolumab plus chemotherapy versus chemotherapy in patients with metastatic nonsquamous NSCLC. Descriptive analyses showed prolonged OS with nivolumab plus chemotherapy in all-randomized and squamous NSCLC populations, suggesting that this combination may benefit patients with untreated metastatic NSCLC. In CheckMate 227 Part 1, first-line nivolumab plus ipilimumab prolonged overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC) and tumor programmed death-ligand 1 (PD-L1) expression ≥1% versus chemotherapy. We report results from CheckMate 227 Part 2, which evaluated nivolumab plus chemotherapy versus chemotherapy in patients with metastatic NSCLC regardless of tumor PD-L1 expression. Seven hundred and fifty-five patients with systemic therapy-naive, stage IV/recurrent NSCLC without EGFR mutations or ALK alterations were randomized 1 : 1 to nivolumab 360 mg every 3 weeks plus chemotherapy or chemotherapy. Primary endpoint was OS with nivolumab plus chemotherapy versus chemotherapy in patients with nonsquamous NSCLC. OS in all randomized patients was a hierarchically tested secondary endpoint. At 19.5 months’ minimum follow-up, no significant improvement in OS was seen with nivolumab plus chemotherapy versus chemotherapy in patients with nonsquamous NSCLC [median OS 18.8 versus 15.6 months, hazard ratio (HR) 0.86, 95.62% confidence interval (CI) 0.69-1.08, P = 0.1859]. Descriptive analyses showed OS improvement with nivolumab plus chemotherapy versus chemotherapy in all randomized patients (median OS 18.3 versus 14.7 months, HR 0.81, 95.62% CI 0.67-0.97) and in an exploratory analysis in squamous NSCLC (median OS 18.3 versus 12.0 months, HR 0.69, 95% CI 0.50-0.97). A trend toward improved OS was seen with nivolumab plus chemotherapy versus chemotherapy, regardless of the tumor mutation status of STK11 or TP53, regardless of tumor mutational burden, and in patients with intermediate/poor Lung Immune Prognostic Index scores. Safety with nivolumab plus chemotherapy was consistent with previous reports of first-line settings. CheckMate 227 Part 2 did not meet the primary endpoint of OS with nivolumab plus chemotherapy versus chemotherapy in patients with metastatic nonsquamous NSCLC. Descriptive analyses showed prolonged OS with nivolumab plus chemotherapy in all-randomized and squamous NSCLC populations, suggesting that this combination may benefit patients with untreated metastatic NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
17秒前
Ophelia完成签到,获得积分10
31秒前
完美世界的应助被科研通管家采纳,获得10
31秒前
QQQQQQ完成签到 ,获得积分10
37秒前
46秒前
56秒前
1分钟前
踏实莛发布了新的文献求助10
1分钟前
2分钟前
2分钟前
NinaKhan657发布了新的文献求助30
2分钟前
2分钟前
2分钟前
现代火车发布了新的文献求助10
2分钟前
WEileen完成签到 ,获得积分0
2分钟前
2分钟前
Herrily完成签到,获得积分10
2分钟前
3分钟前
3分钟前
mayberichard完成签到,获得积分10
3分钟前
美好傲蕾完成签到,获得积分10
3分钟前
忘乎所以完成签到,获得积分10
3分钟前
cloudy完成签到,获得积分10
4分钟前
丰富广缘完成签到,获得积分10
4分钟前
愤怒的衬衫完成签到,获得积分10
4分钟前
求求了给篇文献完成签到,获得积分10
4分钟前
mycn完成签到,获得积分10
4分钟前
开朗雅霜完成签到,获得积分10
4分钟前
温暖友易完成签到,获得积分10
4分钟前
yan完成签到,获得积分10
4分钟前
顺利毛豆完成签到,获得积分10
4分钟前
沐雨汐完成签到,获得积分10
4分钟前
baa完成签到,获得积分10
4分钟前
舒适的妍完成签到,获得积分10
4分钟前
zheng完成签到,获得积分10
4分钟前
花开富贵完成签到,获得积分10
4分钟前
陈微完成签到,获得积分10
4分钟前
完美梦之完成签到,获得积分10
4分钟前
美满尔蓝完成签到,获得积分10
4分钟前
慢波完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195167
求助须知:如何正确求助?哪些是违规求助? 9580893
关于积分的说明 21872961
捐赠科研通 7795146
什么是DOI,文献DOI怎么找? 3437967
关于科研通互助平台的介绍 2561259
邀请新用户注册赠送积分活动 2484678